Evidence map›Paper›PMID 31848730›Full record

ArticlePharmaceutical research2019

High Content Solid Dispersions for Dose Window Extension: A Basis for Design Flexibility in Fused Deposition Modelling.

Rydvikha Govender, Susanna Abrahmsén-Alami, Staffan Folestad, Anette Larsson

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Rydvikha GovenderPharmaceutical Technology and Development, AstraZeneca Gothenburg, Pepparedsleden 1, 43183, Mölndal, Sweden. rydvikha.govender@astrazeneca.com.ORCID http://orcid.org/0000-0003-0265-3075
Susanna Abrahmsén-AlamiPharmaceutical Technology and Development, AstraZeneca Gothenburg, Pepparedsleden 1, 43183, Mölndal, Sweden.
Staffan FolestadPharmaceutical Technology and Development, AstraZeneca Gothenburg, Pepparedsleden 1, 43183, Mölndal, Sweden.
Anette LarssonChemistry and Chemical Engineering, Chalmers University of Technology, Gothenburg, Sweden.
AstraZeneca (Sweden) · SEAstraZeneca (Australia) · AUChalmers University of Technology · SE

Funding

Stiftelsen för Strategisk Forskning ID15-0044
6 · The paper itself

Abstract

purposeThis study uses high drug content solid dispersions for dose window extension beyond current demonstrations using fused deposition modelling (FDM) to; i) accommodate pharmaceutically relevant doses of drugs of varying potencies at acceptable dosage form sizes and ii) enable enhanced dose flexibility via modular dosage form design concepts.

methodsFDM was used to generate ~0.5 mm thick discs of varying diameter (2-10 mm) from melt-extruded feedstocks based on 10% to 50% w/w felodipine in ethyl cellulose. Drug content was determined by UV spectroscopy and dispensing precision from printed disc mass.

resultsMean felodipine content was within ±5% of target values for all print volumes and compositions including contents as high as ~50% w/w. However, poor dispensing precision was evident at all print volumes.

conclusionsIn pursuit of dose flexibility, this successful demonstration of dose window extension using high content solid dispersions preserves FDM design flexibility by maintaining applicability to drugs of varying potencies. The achieved uniformity of content supports the application of varying content solid dispersions to modular dosage form concepts to enhance dose flexibility. However, poor dispensing precision impedes its utilisation until appropriate compatibility between FDM hardware and materials at varying drug contents can be attained.

Indexed as

Drug LiberationTechnology, PharmaceuticalCelluloseDrug CompoundingExcipientsFelodipineCelluloseethyl celluloseExcipientsFelodipinedose flexibilityfused deposition modellingmodular designsolid dispersionuniformity of drug content

Identifiers

PMID31848730
PMCPMC6917630
OpenAlexW2994877350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.